AACR 2025 | The economic benefits of reducing ICI dosage in cancer treatment
Daniel Goldstein, MD, Davidoff Center, Rabin Medical Center, Tel Aviv, Israel, comments on the importance of policy flexibility in expanding access to immune checkpoint inhibitors (ICIs) for cancer. Healthcare systems must be willing to adopt policies that allow for off-label dosing of certain medications to reduce financial toxicity and increase access to care. This has been successfully implemented in various countries and healthcare systems, where lower dosing policies have been put in place. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Payers or healthcare systems or hospitals need to be willing to say, okay, if we’re going to expand access or reduce financial toxicity, then we’re willing to put a policy in place in a healthcare system to say, even if it’s not exactly the labeled dosage, but we’re willing to put a policy in place to say that we support the dosing of a certain drug, even if it’s off-label...
Payers or healthcare systems or hospitals need to be willing to say, okay, if we’re going to expand access or reduce financial toxicity, then we’re willing to put a policy in place in a healthcare system to say, even if it’s not exactly the labeled dosage, but we’re willing to put a policy in place to say that we support the dosing of a certain drug, even if it’s off-label. And that has been done in some countries now. So, for example, lower dosing is being given in Iceland, Sweden, Denmark, Israel, Kaiser Permanente in the US. And so these places have developed policies in order to use lower dosing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
